Objectives The aim of this study is to provide relevant and accurate information on prevalence and treatment patterns of anaemia in Belgian cancer patients. Methods The Anaemia Day 2008 survey was a single visit, multi-centre, non-interventional study in adult cancer patients under systemic therapy (chemotherapy, hormonal, immunological and/or targeted therapy) and/or radiotherapy. Efforts were made to enrol the maximum number of patients seen in each centre that day. Patients signed an informed consent and relevant data were collected from their files, i.e. disease and disease stage, cancer therapy and anti-anaemic treatment, including transfusions and the use of erythropoietin stimulating agents (ESA). A blood count of each included patient was performed. Haemoglobin (Hb) values (grams per decilitre) were classified into four categories to assess the severity of anaemia, as defined by WHO: no anaemia: Hb≥12 g/dL; mild 10≤Hb≤11.9 g/dL; moderate 8≤Hb≤9.9 g/dL; severe Hb< 8 g/dL. Univariate and multivariate analyses were carried out with anaemia as the dependent variable. Results A total of 1,403 eligible patients aged 63±13 years (mean age±SD) were enrolled in 106 oncology or haematology centres. The mean Hb level (±SD) was 11.6 g/dL (±1.8 g/dL) and the prevalence of anaemia (Hb<12 g/dL) was 55.7% (95% CI, 53.1-58.3%), respectively, 35.9% mild, 17.8% moderate and 2.1% severe anaemia. Anaemia was more frequent in females than in males, and in patients with haematological malignancies (73.4%) than in those with solid tumours (51.4%; p<0.001). Anaemia prevalence was higher in hospitalised patients (75.5%) compared to those seen in one-day-clinic (54.3%) or in consultation (33.9%; p<0.001), and in patients treated with chemotherapy (61.3%) compared to those receiving radiotherapy (34.4%) or hormonal therapy (19.5%; p<0.001). There was a clear correlation between severity of anaemia and WHO performance status (p< 0.001). Among anaemic patients, 53.1% received no treatment (mean Hb 10.8±0.9 g/dL). Among the anaemic patients who received therapy for their anaemia (mean Hb 9.7±1.1 g/dL), the most frequent treatments were RBC transfusions (42%), ESA (34.6%), transfusions + ESA (12%), ESA+iron (7.9%) and iron alone (3.5%). Comparison to the ECAS survey shows that there has been no major change in attitude towards anaemia management in the last decade.
Introduction
Anaemia is common in patients with malignancy, particularly if under chemotherapy [1] . The impact of anaemia on the physical and psychological health status of cancer patients is well known [1, 2] . Therefore, optimal management of anaemia appears to be an important component of cancer treatment. Particularly important may be the effect of mild-to-moderate anaemia on patients who might not be treated according to the European Organisation for Research and Treatment of Cancer (EORTC) guidelines [3] , patients with haemoglobin between 10.0 and 11.9 g/dL.
Recent data on prevalence and incidence of anaemia in cancer patients, particularly within the routine practice of individual countries, are almost non-existing. This study describes the methodology of the Anaemia Day and provides patient data that focus on the prevalence of anaemia, the effect of mild, moderate and severe anaemia on performance status, and anaemia treatment patterns.
Material and methods

Study design
The "Anaemia Day 2008" survey is a one visit only, multi-centre and non-interventional study in cancer patients presenting at Belgian oncology and haematology centres. Inclusion criteria were: age 18 years or older, bearing a solid tumour or a haematological malignancy, being under systemic therapy and/or radiotherapy, having a blood count foreseen the day of the scheduled visit and having given a written informed consent.
Data collection
The following data were collected: date of the visit, age, geographical region, gender, WHO performance status, site of visit (hospitalisation, one-day hospital unit, consultation), reason of visit (follow-up, active treatment, supportive care, other), date of the initial diagnosis of cancer, age of the patient at diagnosis. The tumour was classified as solid or haematological and the current tumour extension was reported as primary, locally advanced or metastatic. Recent therapy (last 4 weeks before the recorded visit) was reported as chemotherapy, radiotherapy, hormonal therapy, or other (immunological therapy, targeted therapy, other). For chemotherapy, the intention of treatment (adjuvant, neoadjuvant, advanced stage), the actual number of cycles and the schedule (containing platinum, anthracyclines, taxanes or others) were also recorded.
Blood haemoglobin (Hb) levels (grams per decilitre) were measured on the day of visit and classified into four categories in order to assess the severity of anaemia: none, Hb≥12 g/dL; mild, 10≤Hb≤11.9 g/dL; moderate, 8≤Hb≤ 9.9 g/dL; severe, Hb<8 g/dL. Anaemia-related symptoms occurring during the 4 weeks preceding the day of the survey were also recorded. The following information about antianaemic treatment was collected: time when treatment was started (during past 4 weeks or on day of survey), type of treatment (none, RBC transfusion, erythropoiesis-stimulating agents (ESA), iron supplementation), the Hb level at initiation of treatment and the targeted Hb level.
Statistical analyses
The primary endpoint of the study was prevalence and severity of anaemia (mild, moderate, severe) in Belgian cancer patients treated with systemic therapy and/or radiotherapy in oncology/haematology centres. Secondary endpoints included the description of the characteristics of cancer patients as well as their current management of anaemia.
Results were expressed as mean±standard deviation (SD), median and range for quantitative variables. The relationship between two variables was assessed by the correlation coefficient or by the chi-square test in case of two categorical variables. Mean values from two groups were compared by the Student t test (corrected for unequal variances if necessary) or by a non-parametric test (e.g. Wilcoxon test) when the variable was not normally distributed. Analyses of variance or the non-parametric Kruskal-Wallis test were applied for the comparison of several groups. The classical chi-square test for contingency tables was used for comparing proportions.
Logistic regression analysis was used to measure the association between anaemia and a set of covariates. The odds ratio (OR) was computed with its 95% confidence interval (CI) to measure the association between the risk of anaemia and the covariates. Ordinal logistic regression analysis was also used to relate the severity of anaemia with the same set of covariates.
Results were considered to be significant at the 5% significant level (p<0.05).
Results
A total of 1,403 eligible patients aged 63.1±13.0 years were enrolled in 106 oncology or haematology centres. The mean time (±SD) since first diagnosis of cancer was 2.1± 3.2 years (range, 0-24 years). Table 1 summarises the demographics and patient characteristics.
For the 1,403 included patients, the prevalence of anaemia was 55.7% with a mean Hb level (±SD) of 11.6 ± 1.8 g/dL. The classification of the cancer patients according to their haemoglobin levels revealed that 44.3% were not anaemic, 35.9% presented a mild anaemia, 17.8% a moderate anaemia and 2.1% a severe anaemia. Table 2 displays anaemia prevalence by tumour type and extent of cancer. Only 13.8% of patients with solid tumours had moderate or severe anaemia, while the proportion was 44.2% in those with haematological malignancies (p< 0.001). In solid tumour patients, the level of anaemia differed significantly according to the location of the primary tumour, with more moderate and severe anaemia in patients with gynaecological and head-and-neck tumours (p<0.0001). For haematological malignancies, more moderate and severe anaemia were reported in patients with myelodysplastic syndromes (p<0.0001). Anaemia was significantly associated with the extent of cancer. Patients with metastasis or locally advanced cancer had significantly more often moderate to severe anaemia than patients with only a localised solid tumour.
There was a trend for higher incidence of anaemia in female. From a multivariate standpoint, female were 1.8 times more at risk of anaemia than men. Table 3 shows the prevalence of anaemia according to the treatment received. When analysed by type of treatment at enrolment, 61.3% of patients receiving chemotherapy, 34.4% of those receiving radiotherapy and 19.5% of those receiving hormonal therapy were anaemic.
There was a clear correlation between the severity of anaemia and WHO performance status (p<0.0001). There were more patients at enrolment with poor-performance status at lower Hb levels than at higher Hb levels. WHO scores of 2-4 were recorded for 65% of patients with Hb< 8.0 g/dL, 48% of those with Hb between 8.0 and 9.9 g/dL, 22% of those with Hb between 10.0 and 11.9 g/dL and 1% of those with Hb>12 g/dL (Table 4) .
Of patients who were ever anaemic (the day of survey or past 4 weeks preceding the visit; n=782), 53.1% received no treatment. The majority (83%) of untreated anaemic patients had Hb levels between 10.0 and 11.9 g/dL; 17% had Hb levels between 8.0 and 9.9 g/dL, and 0.1% had Hb levels <8 g/dL. Table 5 shows the percentage of patients who received treatment for their anaemia. For the 46.9% of patients who received treatment, the most frequent therapy was transfusion, either alone (42%) or in combination with ESA (12%). The frequencies of ESA treatment alone or with iron were 35% and 8%, respectively, and that of iron alone was 3.5%. The mean Hb level for initiating treatment was 9.7 g/dL in our study, with the level for transfusion being 9.2 g/dL and the level for ESA being 10.2 g/dL.
Discussion
This survey shows that anaemia is still frequently observed in Belgian cancer patients under treatment, with a general prevalence of 55.7%, including 20% with moderate to severe anaemia. Anaemia was more frequent in patients with haematological tumours (73.4%) than in patients with solid tumours (51.4%). Among solid tumour patients, anaemia was more severe in patients with gynaecological and head-and-neck tumours. Among patients with haematological malignancies, anaemia was more prominent in those with myelodysplastic syndromes. The prevalence of anaemia found in our survey is higher than in previous reports. In Japanese and Turkish studies, 44% of the patients were anaemic at the start of their chemotherapy [4, 5] . The prevalence of anaemia at enrolment in the European and Australian Cancer Anaemia surveys (ECAS, ACAS) was 39% and 35%, respectively, with 10% and 8% having moderate to severe anaemia [1, 6] . This difference could be explained by the exclusion of untreated patients in the ECAS and ACAS studies. In the ECAS study, the prevalence of anaemia among patients receiving chemotherapy was 62.7%, a figure comparable to ours.
We observed a clear correlation between anaemia and low-performance status. More than half of the patients with severe anaemia had a WHO score of 2-4, but performance scores of 2-4 were also noted for 22% of patients with haemoglobin levels between 10.0 and 11.9 g/dL. This relationship between anaemia and low-performance status was already demonstrated in the ECAS study and is consistent with the correlation reported between the increase in haemoglobin levels with ESA and the improvement of quality of life [7] [8] [9] . In the large trial of Demetri et al., patients who achieved an increase in haemoglobin level of 2 g/dL or greater had the largest increase in quality of life, even in the case of progressive disease [7] . Despite evidence that even mild anaemia can adversely affect quality of life, many clinicians still don't treat anaemic patients. In our survey, 53.1% of the anaemic patients received no treatment for their anaemia. Most of them (35.4%) had haemoglobin levels between 10.0 and 11.9 g/dL, but another 15% of the untreated patients had a haemoglobin level<10 g/dL. In the ECAS study, anaemia treatment was initiated in approximately 40% of anaemic patients [1] .
In our survey, the most frequently used treatments were RBC transfusions (42%), ESA (34.6%), transfusions+ESA (12%), ESA+iron (7.9%) or iron alone (3.5%). In comparison, in the ECAS and ACAS studies, transfusions were given to 17% and 36% and ESA to 15% and 2% of the patients, respectively. The mean haemoglobin level for initiating treatment was 9.7 g/dL in our study, with the level for transfusion being 9.2 g/dL and that for ESA 10.2 g/dL. The trigger for initiating transfusions was 9.7 g/dL both in the ECAS and ACAS studies [1, 6] .
Several studies with ESA have raised a number of safety issues, including an increased risk of thromboembolic events and a negative impact on survival [10] [11] [12] . In a recent meta-analysis based on individual patient data from randomised trials, the HR for overall mortality was 1.06 (95% CI, 1.00-1.12) [13] . This meta-analysis also included patients not receiving treatment for their cancer or receiving treatments other than chemotherapy The HR of death was 1.10 (95% CI, 0.98-1.24) in patients treated with chemotherapy and few of the included trials were restricted to the approved indications of ESA, making it difficult to generalise these results.
The EORTC guidelines recommend that ESAs should be initiated at an Hb level of 9-11 g/dL in cancer patients receiving chemotherapy or radiochemotherapy, based on anaemia-related symptoms [3] . And ESA therapy may be considered in selected asymptomatic patients receiving chemotherapy with a Hb level of 11-11.9 g/dL if this would prevent a further decline in Hb. Such a decision should take into account an individual's Hb level and the type, intensity, and duration of chemotherapy. The aim of treatment with ESA is to achieve an Hb concentration of about 12 g/dL, without exceeding this target. For that reason, the new label for ESA suggests to initiate treatment to patients with syptomatic anaemia in order to increase haemoglobin, without exceeding the target of 12 g/dL.
This study indicates that Belgian physicians respect these recommendations: the Hb trigger to start ESA treatment was 10.2 g/dL and the target was 11.6 g/dL. Our Belgian treatment patterns are congruent with the findings from the Anaemia Cancer Treatment Study (ACT), where most patients were treated per guidelines [14] . In the ACT study, after treatment with ESA, the Hb increased by 1.34 g/dl, without concomitant rise in WHO score. We were not able to analyse the correlation between use of ESA and anaemia-related symptoms because of the design of the study that was a one-day snapshot of a large population of cancer patients. In this survey, only patients under systemic therapy or radiotherapy were included. For this reason, it is impossible to assess potential off-label uses, but as in Belgium reimbursement of ESA is restricted to patients under chemotherapy, such offlabel use would be expected to be very low.
In conclusion, this survey shows that cancer-related anaemia is still frequently observed in patients in Belgium and that it correlates significantly with poor performance status. Even if in our survey ESA were used more frequently than 10 years ago, a significant proportion of patients with moderate and probably symptomatic anaemia who could be treated for anaemia according to the EORTC guidelines did not. 
